Acellbia vs HLX01
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Rheumatoid Arthritis
Shared mechanism: CD20 · full Rheumatoid Arthritis pipeline
Acellbia
Marketed by Biocad
NCT02744196 · Phase 3 · completed
This was a randomized, triple-blinded, placebo-controlled trial with 159 patients and a validated disease-response primary endpoint (ACR20). The result was clearly positive: 65.7% of Acellbia-treated patients achieved ACR20 at week 24 versus 29.4% on placebo (p<0.0001).
Reported efficacy
Percentage of patients who developed ACR20 response on 24 week of therapy (Week 24): ACR20 response at Week 24 (ALTERRA trial, N=159): Acellbia+MTX 65.7% vs Placebo+MTX 29.4% (p<0.0001); difference 36.3% (95% CI 19.27-53.28%) (met)
Result source: NCT02744196
HLX01 · Hanlikang
Marketed by Shanghai Henlius Biotech
NCT03522415 · Phase 3 · completed
This randomised, quadruple-blind trial compared HLX01 plus methotrexate with placebo plus methotrexate in 275 patients with rheumatoid arthritis. At 24 weeks, 60.7% of patients on HLX01 reached an ACR20 response against 35.9% on placebo (P<0.001), a clear result on a validated measure of disease activity.
No aligned efficacy figure on record for this race.
Results for Rheumatoid Arthritis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Acellbia | HLX01 |
|---|---|---|
| ACR20 | 65.7% vs 29.4%a+36.3 vs placeboNCT02744196 | 60.7% vs 35.9%a+24.8 vs placeboNCT03522415 |
| ACR50 | —Not posted · NCT02744196 | —Not posted · NCT03522415 |
| ACR70 | —Not posted · NCT02744196 | —Not posted · NCT03522415 |
| DAS28-CRP remission | —Not posted · NCT02744196 | —Not posted · NCT03522415 |
| HAQ-DI, change | —Not posted · NCT02744196 | —Not posted · NCT03522415 |
| Modified Sharp score, change | —Not posted · NCT02744196 | —Not posted · NCT03522415 |
ACR20
- Acellbia
- 65.7% vs 29.4%a+36.3 vs placeboNCT02744196
- HLX01
- 60.7% vs 35.9%a+24.8 vs placeboNCT03522415
ACR50
- Acellbia
- —Not posted · NCT02744196
- HLX01
- —Not posted · NCT03522415
ACR70
- Acellbia
- —Not posted · NCT02744196
- HLX01
- —Not posted · NCT03522415
DAS28-CRP remission
- Acellbia
- —Not posted · NCT02744196
- HLX01
- —Not posted · NCT03522415
HAQ-DI, change
- Acellbia
- —Not posted · NCT02744196
- HLX01
- —Not posted · NCT03522415
Modified Sharp score, change
- Acellbia
- —Not posted · NCT02744196
- HLX01
- —Not posted · NCT03522415
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Acellbia's landscape · HLX01's landscape